Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: philip oraby who wrote (636)	12/29/2007 4:50:33 PM
From: Icebrg	Respond to of 668

>>Is this a step forward for Cris?>> Yes, definitively. In the future they will not have to pay anything to keep those patents valid. On the other hand, that's about it. >>Can we really expect pps to improve?>> They (or Genenetech) will have to show some progress before anything drastic will happen to the share price. The new compounds they are developing have not been proven in any way yet, so I cannot really see much improvement in the short term. On the third hand, the company now has a market cap of 48 mUSD, although cash on hand as at end of Q3 was 41 mUSD. An enterprise value of only 7 mUSD seems to me to be on the low side. So, there is perhaps some scope for an improvement. But this one flies under most of the radars set up at Wall Street, so there is no guarantee for anything. Erik